Ayala Pharmaceuticals Inc. Common Stock (NASDAQ:AYLA)

Home >> Stock >> Ayala Pharmaceuticals Inc. Common Stock >> Ratio

Blog+More

OECD cuts the global economic growth forecast from 3.5% to 3.3% for the current fiscal year 2019-2020.

Rose Prince

2019-03-27 11:28:00 Wednesday ET

OECD cuts the global economic growth forecast from 3.5% to 3.3% for the current fiscal year 2019-2020.

OECD cuts the global economic growth forecast from 3.5% to 3.3% for the current fiscal year 2019-2020. The global economy suffers from economic protraction

+See More

Tim Berners-Lee suggests that several tech titans might need to be split up in response to some recent data breach and privacy concerns.

Chanel Holden

2018-11-09 11:35:00 Friday ET

Tim Berners-Lee suggests that several tech titans might need to be split up in response to some recent data breach and privacy concerns.

The Internet inventor Tim Berners-Lee suggests that several tech titans might need to be split up in response to some recent data breach and privacy concern

+See More

The Economist Intelligence Unit (EIU) continues to track major business risks in light of volatile stock markets.

Fiona Sydney

2019-01-11 10:33:00 Friday ET

The Economist Intelligence Unit (EIU) continues to track major business risks in light of volatile stock markets.

The Economist Intelligence Unit (EIU) continues to track major business risks in light of volatile stock markets, elections, and geopolitics. EIU monitors g

+See More

Apple CEO Tim Cook maintains a frugal low-key lifestyle.

Jonah Whanau

2019-10-11 13:40:00 Friday ET

Apple CEO Tim Cook maintains a frugal low-key lifestyle.

Apple CEO Tim Cook maintains a frugal low-key lifestyle. With $625 million public wealth, Cook leads the $1 trillion tech titan Apple in the post-Jobs era.

+See More

The recent Bristol-Myers Squibb acquisition of American Celgene is the $90 billion biggest biotech deal in history.

Jacob Miramar

2019-01-10 17:31:00 Thursday ET

The recent Bristol-Myers Squibb acquisition of American Celgene is the $90 billion biggest biotech deal in history.

The recent Bristol-Myers Squibb acquisition of American Celgene is the $90 billion biggest biotech deal in history. The resultant biopharma goliath would be

+See More

Empirical tests of multi-factor models for asset return prediction

Apple Boston

2022-02-25 00:00:00 Friday ET

Empirical tests of multi-factor models for asset return prediction

Empirical tests of multi-factor models for asset return prediction  The capital asset pricing model (CAPM) of Sharpe (1964), Lintner (1965), and Bla

+See More